Key result
Deep next-generation sequencing revealed low-level mosaicism for a PRKAR1A defect in blood and saliva, alongside a second somatic mutation in the adrenal adenoma.
Case Report (n=1)
This is the first reported case of PPNAD and an adenoma forming due to complete inactivation of PRKAR1A from a combination of low-level mosaicism and a second somatic mutation.
Answers are grounded in this paper and cite their sources.
May prompt mosaicism consideration in PRKAR1A-PPNAD; hypothesis-generating and leaves open broader validation.
Context Primary pigmented nodular adrenocortical disease (PPNAD) is a rare cause of ACTH-independent Cushing syndrome (CS) associated mostly with Carney complex (CNC), a rare autosomal dominant multiple neoplasia syndrome. More than two-thirds of familial cases and approximately one-third of sporadic cases of CNC harbor germline inactivating PRKAR1A defects. Increasingly sensitive technologies for the detection of genetic defects such as next-generation sequencing (NGS) have further highlighted the importance of mosaicism in human disease. Case Description A 33-year-old woman was diagnosed with ACTH-independent CS with abdominal computed tomography showing bilateral micronodular adrenal hyperplasia with a left adrenal adenoma. She underwent left adrenalectomy with pathology demonstrating PPNAD with a 1.5-cm pigmented adenoma. DNA analysis by Sanger sequencing revealed 2 different PRKAR1A variants in the adenoma that were absent from DNA extracted from blood and saliva: c.682C > T and c.974-2A > G. “Deep” NGS revealed that 0.31% of DNA copies extracted from blood and saliva did in fact carry the c.682C > T variant, suggesting low-level mosaicism for this defect. Conclusions We present a case of PPNAD due to low-level mosaicism for a PRKAR1A defect which led to the formation of an adenoma due to a second, adrenal-specific, somatic PRKAR1A mutation. The identification of mosaicism for PRKAR1A, depending on the number and distribution of cells affected has implications for genetic counseling and tumor surveillance. This is the first recorded case of a patient with PRKAR1A mosaicism, PPNAD, and an adenoma forming due to complete inactivation of PRKAR1A in adrenal tissue from a second, somatic-only, PRKAR1A coding sequence mutation.
No takes yet. Share an insight, caveat, or question.
Kamilaris et al. (2021) conducted a case report in ACTH-independent Cushing syndrome and primary pigmented nodular adrenocortical disease (n=1). Genetic sequencing (Sanger and next-generation sequencing) was evaluated on Identification of PRKAR1A variants. Deep next-generation sequencing revealed low-level mosaicism for a PRKAR1A defect in blood and saliva, alongside a second somatic mutation in the adrenal adenoma.
Synapse has enriched 10 related papers. Consider them for comparative context: